High dividend yields are often a sign of trouble, which makes Enbridge's 5.6% yield very interesting.
Gilead Sciences reported positive Phase 3 results for Trodelvy in combination with Keytruda in first-line PD-L1+ metastatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results